Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia phytofirmans UPF0133 protein Bphyt_1827 (Bphyt_1827) CSB-YP464502BXU
CSB-EP464502BXU
CSB-BP464502BXU
CSB-MP464502BXU
CSB-EP464502BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Co-chaperone protein hscB homolog (hscB) CSB-YP464503BXU
CSB-EP464503BXU
CSB-BP464503BXU
CSB-MP464503BXU
CSB-EP464503BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Putative ribosome biogenesis GTPase RsgA (rsgA) CSB-YP464504BXU
CSB-EP464504BXU
CSB-BP464504BXU
CSB-MP464504BXU
CSB-EP464504BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L33 (rpmG) CSB-YP464505BXU
CSB-EP464505BXU
CSB-BP464505BXU
CSB-MP464505BXU
CSB-EP464505BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Bifunctional protein GlmU (glmU) CSB-YP464506BXU
CSB-EP464506BXU
CSB-BP464506BXU
CSB-MP464506BXU
CSB-EP464506BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans UPF0271 protein Bphyt_3743 (Bphyt_3743) CSB-YP464507BXU
CSB-EP464507BXU
CSB-BP464507BXU
CSB-MP464507BXU
CSB-EP464507BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 30S ribosomal protein S4 (rpsD) CSB-YP464508BXU
CSB-EP464508BXU
CSB-BP464508BXU
CSB-MP464508BXU
CSB-EP464508BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 30S ribosomal protein S14 (rpsN) CSB-YP464509BXU
CSB-EP464509BXU
CSB-BP464509BXU
CSB-MP464509BXU
CSB-EP464509BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 30S ribosomal protein S17 (rpsQ) CSB-YP464510BXU
CSB-EP464510BXU
CSB-BP464510BXU
CSB-MP464510BXU
CSB-EP464510BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L2 (rplB) CSB-YP464511BXU
CSB-EP464511BXU
CSB-BP464511BXU
CSB-MP464511BXU
CSB-EP464511BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L7/L12 (rplL) CSB-YP464512BXU
CSB-EP464512BXU
CSB-BP464512BXU
CSB-MP464512BXU
CSB-EP464512BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans ATP synthase epsilon chain (atpC) CSB-YP464513BXU
CSB-EP464513BXU
CSB-BP464513BXU
CSB-MP464513BXU
CSB-EP464513BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Flavoprotein wrbA (wrbA) CSB-YP464514BXU
CSB-EP464514BXU
CSB-BP464514BXU
CSB-MP464514BXU
CSB-EP464514BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase (metE), partial CSB-YP464515BXU
CSB-EP464515BXU
CSB-BP464515BXU
CSB-MP464515BXU
CSB-EP464515BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans HTH-type transcriptional regulator BetI (betI) CSB-YP464516BXU
CSB-EP464516BXU
CSB-BP464516BXU
CSB-MP464516BXU
CSB-EP464516BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans L-rhamnose mutarotase (rhaM) CSB-YP464517BXU
CSB-EP464517BXU
CSB-BP464517BXU
CSB-MP464517BXU
CSB-EP464517BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium botulinum Carbamoyl-phosphate synthase large chain (carB), partial CSB-YP464518DUG
CSB-EP464518DUG
CSB-BP464518DUG
CSB-MP464518DUG
CSB-EP464518DUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium botulinum Putative Holliday junction resolvase (CLL_A1176) CSB-YP464519DUG
CSB-EP464519DUG
CSB-BP464519DUG
CSB-MP464519DUG
CSB-EP464519DUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium botulinum Asparagine--tRNA ligase (asnS) CSB-YP464520DUG
CSB-EP464520DUG
CSB-BP464520DUG
CSB-MP464520DUG
CSB-EP464520DUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium botulinum Formate--tetrahydrofolate ligase (fhs), partial CSB-YP464521DUG
CSB-EP464521DUG
CSB-BP464521DUG
CSB-MP464521DUG
CSB-EP464521DUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>